Related Experiment Video
Updated: May 24, 2026
Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
Published on: August 2, 2022
Systemic treatment of brain metastases in HER2-positive breast cancer: current status and future directions
1Department of Clinical Oncology, Cairo University Hospital, Cairo, Egypt.
Abstract:
In recent years, brain metastases have emerged as a main challenge affecting the morbidity and mortality of patients with HER2-positive metastatic breast cancer. In the era following trastuzumab, approximately 30% of these patients develop brain metastases. Trastuzumab does not cross the blood-brain barrier, hence its role is limited to controlling extra-CNS metastases. Lapatinib emerged as a potential candidate; however, its use as a single agent was associated with modest responses. Combination with capecitabine was associated with good results, particularly in patients with newly diagnosed brain metastases. In this article, we discuss the role of trastuzumab and lapatinib in patients with HER2-positive breast cancer with brain metastases. We also highlight the complex structure of the blood-brain barrier and elucidate different potential strategies that could be useful in improving drug delivery.
Insights
Brain metastases are a significant challenge for HER2-positive breast cancer patients. Trastuzumab and lapatinib show promise, but drug delivery across the blood-brain barrier remains a key hurdle.
Area of Science:
- Oncology
- Pharmacology
- Neuroscience
Background:
- Brain metastases are a major cause of morbidity and mortality in HER2-positive metastatic breast cancer.
- Approximately 30% of patients develop brain metastases after trastuzumab treatment.
- Trastuzumab's limited ability to cross the blood-brain barrier restricts its efficacy against CNS metastases.
Purpose of the Study:
- To review the roles of trastuzumab and lapatinib in managing HER2-positive breast cancer with brain metastases.
- To discuss the challenges posed by the blood-brain barrier in drug delivery.
- To explore strategies for enhancing drug delivery to the brain.
Main Methods:
- Literature review of clinical studies and pharmacological data.
- Analysis of treatment outcomes for trastuzumab and lapatinib in patients with brain metastases.
- Discussion of the physiological properties of the blood-brain barrier.
Main Results:
- Trastuzumab is effective for extra-CNS metastases but limited for brain metastases.
- Lapatinib monotherapy shows modest responses in brain metastases.
- Combination therapy with lapatinib and capecitabine demonstrates good results, especially in newly diagnosed brain metastases.
Conclusions:
- Effective management of HER2-positive breast cancer with brain metastases requires strategies that overcome the blood-brain barrier.
- Further research into drug delivery mechanisms is crucial for improving patient outcomes.
- Combination therapies may offer improved efficacy for CNS metastases.
Related Concept Videos
02:56Treatment Resistant Cancers
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:56Treatment Resistent Cancers
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...